Glaucoma supplement trial fizzles: MEMOPTIC study halted early
NCT ID NCT04499157
First seen Jun 12, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This study tested whether a daily tablet called MEMOPTIC (containing citicoline, magnesium, and Ginkgo biloba) could help preserve vision in people with open-angle glaucoma when added to their usual eye-pressure-lowering treatments. The trial planned to follow 15 patients for two years, but it was terminated early. Because of the small size and early stop, no firm conclusions can be drawn about whether MEMOPTIC helps protect vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPEN-ANGLE GLAUCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Amiens
Amiens, 80480, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MEMOPTIC (a tablet combining citicoline, magnesium, and Ginkgo biloba)
What this could lead to
If it worked, MEMOPTIC might help preserve vision in glaucoma patients when added to standard pressure-lowering treatments.
What could go wrong
The trial was terminated early and included only 15 people, so results are very limited. It is unclear if the supplement provides any real benefit over standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.